StrVCTVRE

StrVCTVRE predicts the pathogenicity of structural variants (SVs), specifically deletions and duplications overlapping exons larger than 50 base pairs, to prioritize likely disease-causing variants.


Key Features:

  • Pathogenicity Prediction: Predicts whether exon-overlapping deletions and duplications are pathogenic or benign.
  • Random Forest Classifier: Uses a random forest classifier that integrates gene importance, coding-region characteristics, conservation levels, expression data, and exon structure.
  • Feature Integration: Incorporates expression and conservation alongside gene and exon features, which are absent from current SV classification guidelines.
  • Training Set Construction: Builds a size-matched training set of rare, putatively benign and pathogenic SVs compiled from multiple resources.
  • Performance Metrics: Shows high accuracy across a wide range of SV sizes on independent test sets, reducing the number of SVs requiring further consideration by about half while maintaining 90% sensitivity.

Scientific Applications:

  • Clinical Prioritization: Prioritizes SVs in probands lacking an immediately compelling single variant to aid case resolution.
  • Long-read Sequencing Diagnostics: Assesses exon-overlapping SV pathogenicity to maximize diagnostic yield from long-read sequencing.

Methodology:

Implements a random forest classifier that integrates gene importance, coding-region features, conservation, expression, and exon structure; trains on a size-matched set of rare putatively benign and pathogenic SVs compiled from multiple resources; evaluates performance on independent test sets.

Topics

Collections

Details

License:
MIT
Maturity:
Mature
Cost:
Free of charge
Tool Type:
command-line tool, web application
Operating Systems:
Linux
Programming Languages:
Python
Added:
4/12/2022
Last Updated:
11/24/2024

Operations

Publications

Sharo AG, Hu Z, Sunyaev SR, Brenner SE. StrVCTVRE: A supervised learning method to predict the pathogenicity of human genome structural variants. The American Journal of Human Genetics. 2022;109(2):195-209. doi:10.1016/j.ajhg.2021.12.007. PMID:35032432. PMCID:PMC8874149.

PMID: 35032432
PMCID: PMC8874149
Funding: - National Heart, Lung, and Blood Institute: R01 HG009141, UM1 HG008900 - National Institutes of Health: P01 AI138962 - National Science Foundation: DGE 1752814

Documentation

Downloads

Links